Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| ServiceNow | Marvell Technology | Eli Lilly and Company | |
|---|---|---|---|
| Moat rating | narrow The FY2025 10-K shows RPO of $28.2 billion, up 27%; customers above $5 million of ACV at 603, 502 and 420 as of December 31 2025, 2024 and 2023; revenue of $13,278 million, up 21%; and a 98% renewal rate for three years. That rate cannot prove durability: the filing computes it excluding "changes in price or users," says it "does not reflect increased or decreased purchases," and warns "period-to-period comparison of renewal rates may not be meaningful." The company also calls its market "characterized by fragmentation, low barriers to entry." Real switching costs plus compounding large accounts support narrow; wide would need durability proof this filing lacks. | narrow FY2026 10-K (filed 2026-03-11): differentiated platform IP — over 10,000 issued patents and pending applications as of 2026-01-31, plus a proven custom ASIC platform leveraging ultra-high-speed SerDes, silicon photonics, co-packaged optics and custom HBM — but Marvell itself calls its markets 'intensely competitive' with 'pricing pressures', notes customers 'have chosen to develop certain semiconductor products internally', and discloses two >=10% customers with the ten largest at 82% of FY2026 net revenue. Real, defensible IP in a concentrated, contestable customer base = narrow, not wide. https://www.sec.gov/Archives/edgar/data/1835632/000183563226000011/mrvl-20260131.htm | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. |
| Moat type | switching costs The binding force is architecture and configuration. The filing describes "a multi-instance architecture that provides each customer with a dedicated application layer and database," an ITOM product that "maintains a single record of all IT configurable items," and products built to "integrate with existing workflows rather than replace them." Once that record and its integrations are configured, replacement becomes a re-platforming program — our inference, as the filing quantifies no switching cost. Not IP: it holds "over 2,000 issued U.S. and foreign patents" but is not "materially dependent on any single patent." Not network effects. | intangibles ip The moat rests on hard-to-replicate mixed-signal IP: the 10-K describes the custom ASIC platform built on ultra-high-speed SerDes, ARM compute, security, storage, silicon photonics and advanced packaging (die-to-die interconnects, chiplets, CPO, custom HBM), with multiple 5nm designs executed, 3nm in progress and a 2nm platform in development; a secondary switching-cost element comes from multi-year custom design wins co-developed to individual customer specifications. https://www.sec.gov/Archives/edgar/data/1835632/000183563226000011/mrvl-20260131.htm | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. |
| Leadership | clear leader The call is scoped to IT service management. Apps Run The World's 2024 ITSM ranking (page dated 23 July 2025) places ServiceNow first at 44.4% share, ahead of Atlassian, BMC, GoTo and Ivanti, in an $11.4 billion market where the top ten hold 83.3%. Scale corroborates: about 8,700 customers, 29,187 employees, $13,278 million of revenue, $28.2 billion of RPO. References to "two decades partnering with enterprise customers" and process knowledge "that cannot be readily replicated" are the filing's own characterisation. Outside ITSM it is weaker: one of six Leaders in the 2025 Gartner LCAP quadrant, and tenth of ten in CRM behind Salesforce at 26.1%. | co leader Leader in its optics niche, #2 in custom silicon: ~60% of high-end PAM4 DSP share (36kr, 2026-06-27, https://eu.36kr.com/en/p/3870758441178373) but an estimated 20-25% of custom AI ASIC design services versus Broadcom's ~70% (hashrateindex, 2026-05-13, https://hashrateindex.com/blog/design-partners-ai-asic-market-part-2/) — net, a co-leader in AI data-center connectivity/custom silicon behind Broadcom overall. | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. |
| Pricing power | moderate The filing discloses no average selling price, no net revenue retention and no pricing data, and the renewal rate is no proxy — it "does not reflect increased or decreased purchases" and excludes "changes in price or users." Revenue up 21%, the $5 million-plus cohort up about 20% annually and RPO up 27% are all consistent with expansion at flat pricing. Margins cut the other way: subscription gross profit fell to 80% from 82% with no stated cause, and professional services gross loss widened to 5% from 2%. One real lever is that "certain AI and data solutions include a consumption-based pricing component." | moderate The 10-K characterizes Marvell's markets as having 'pricing pressures' and intensifying competition (https://www.sec.gov/Archives/edgar/data/1835632/000183563226000011/mrvl-20260131.htm), yet the Q1 FY2027 release reports 52.1% GAAP / 58.9% non-GAAP gross margin on record revenue (https://www.sec.gov/Archives/edgar/data/1835632/000183563226000014/q127_8kx522026ex-991.htm) — differentiated-IP margins, tempered by hyperscaler buyer power. | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. |
| Summary | ServiceNow sells a workflow platform that sits on top of, rather than replaces, an enterprise's existing systems. Each customer gets a dedicated application layer and database, ITOM maintains a single record of all IT configurable items, and products integrate with existing workflows rather than replace them; once that record and its integrations span IT, HR and customer service, displacement becomes a re-platforming exercise. The evidence is in large commitments: $5 million-plus ACV customers rose from 420 to 502 to 603, and RPO reached $28.2 billion, up 27%, against $13,278 million of FY2025 revenue. The moat is bounded by a market the company itself calls fragmented with low barriers to entry, by larger rivals that can bundle or cut price, and by falling subscription gross margin, 82% to 80%. | Marvell is a fabless data-infrastructure silicon supplier whose center of gravity has shifted decisively to the AI data center: the data center end market was $6,100.3M, 74% of FY2026 revenue, up from 40% two fiscal years earlier (FY2026 10-K). Its strongest position is electro-optics — in high-end PAM4 optical DSPs for 400G+ transceivers it holds roughly 60% share on Inphi-inherited SerDes/FEC IP, with Broadcom above 30%, the two together over 90% (36kr, 2026-06-27). In custom AI silicon it is the structural #2 design partner at an estimated 20-25% of the custom AI ASIC design-services market versus Broadcom's ~70%, anchored by AWS Trainium and Microsoft Maia wins (hashrateindex, 2026-05-13). The Q1 FY2027 release (2026-05-27) shows the flywheel turning — record $2.418B revenue (+28% YoY), Q2 guided to $2.7B mid-point (+35% YoY), management citing 'exceptional AI-related bookings' across 800G/1.6T optics, 51.2T switches, CPO/NPO and custom XPU — and the Celestial AI (Photonic Fabric) and XConn (PCIe/CXL switching) acquisitions closed in February 2026 extend the interconnect moat toward scale-up fabrics. The offsets that keep the moat narrow are in Marvell's own filing: intense competition (AMD, Alchip, Astera, Ayar, Broadcom, Credo, GUC, Lightmatter and others), hyperscaler in-housing risk, and heavy customer concentration. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." |
| Chain position | Enterprise workflow platform layered on top of customers' existing systems of record. It consumes public cloud capacity (named relationships with AWS, Google, Microsoft and NVIDIA) plus its own data centers, and reaches customers through a direct sales force, global system integrators (Accenture, Deloitte, EY, Infosys, KPMG) and resale partners. Microsoft is named as both partner and competitor. | Fabless supplier spanning 'data center core to network edge': it sits between hyperscaler AI compute (custom XPU/XPU-attach ASICs) and the optical layer (PAM4/coherent DSPs, CPO/LPO, DCI, AEC, PCIe retimers), outsourcing fabrication to independent CMOS foundries; the Feb-2026 Celestial AI and XConn acquisitions push it further into scale-up photonic fabric and PCIe/CXL/UALink switching (FY2026 10-K, https://www.sec.gov/Archives/edgar/data/1835632/000183563226000011/mrvl-20260131.htm). | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.20 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. |